Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 4, 2004 - Issue 6
Submit an article Journal homepage
26
Views
0
CrossRef citations to date
0
Altmetric
Review

Outcomes associated with inhaled corticosteroid use in asthma and COPD: an update

Monali J Bhosle The University of Texas Health Science Center, School of Public Health, E-345, 1200 Hermann Pressler, Houston, TX 77030, USA. [email protected]
,
Rahul A Shenolikar The University of Texas Health Science Center, School of Public Health, E-345, 1200 Hermann Pressler, Houston, TX 77030, USA. [email protected]
,
Amit S Kulkarni The University of Texas Health Science Center, School of Public Health, E-345, 1200 Hermann Pressler, Houston, TX 77030, USA. [email protected]
&
Rajesh Balkrishnan The University of Texas Health Science Center, School of Public Health, E-345, 1200 Hermann Pressler, Houston, TX 77030, USA. [email protected]
Pages 645-656 | Published online: 09 Jan 2014

References

  • Blumenthal M. The immunopathology and genetics of asthma. Minn. Med. 87, 53–56 (2004).
  • Lethbridge-Cejku M, Schiller JS, Bernadel L. Summary Health Statistics for US Adults: National Health Interview Survey, 2002. Data from the National Health Interview Survey. US Department of Health and Human Services, Centers for Disease Control and Prevention National Center for Health Statistics, MD, USA (2004).
  • Murray CJL, Lopez AD, Mathers CD, Stein C. The Global Burden of Disease 2000 Project: global programme on evidence for health policy discussion, paper 36. WHO, Geneva, Switzerland (2001).
  • Postma DS, Kerstjens HAM. Are inhaled glucocorticosteroids effective in chronic obstructive pulmonary disease? Am. Respir. Crit. Care Med. 160,66–71 (1999).
  • Hurd S. The impact of COPD on lung health worldwide epidemiology and incidence. Chest 117,1–4 (2000).
  • Pauwels RA, Buist AS, Calverley PM et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. 163, 1256–1276 (2001).
  • •Provides information on updated international guidelines on chronic obstructive pulmonary disease (COPD) management.
  • Suisse S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 168,49–53 (2003).
  • Singh V, Sinha HV, Gupta R. Barriers in the management of asthma and attitudes towards complementary medicine. Respir. Med. 96,835–840 (2002).
  • Michaud CM, Murray CJ, Bloom BR. Burden of disease-implications for future research. JAMA 285,535–539 (2001).
  • Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349,1498–1504 (1997).
  • Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Cochrane Database Syst. Rev 2, CD004109 (2004).
  • National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma. Update on selected topics — 2002. J. Allergy Clin. Immunol. 110, S141—S219 (2002).
  • Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N EngL J. Med. 12(343), 1064–1069 (2000).
  • Agertoft L, Pedersen S. Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide. Am. J Respir. Crit. Care Med. 157,178–183 (1998).
  • Bisgaard H, Allen D, Milanowski J, Kalev I, Willits L, Davies P Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 113, 87–94 (2004).
  • Griffiths AL, Sim D, Strauss B, Rodda C, Armstrong D, Freezer N. Effect of high-dose fluticasone propionate on bone density and metabolism in children with asthma. Pediatr. Pulmonol. 37,116–121 (2004).
  • Ramsdell JW, Fish L, Graft D et al. A controlled trial of twice daily triamcinolone oral inhaler in patients with mild-to-moderate asthma. Ann. Allergy Asthma Immunol. 80,385–390 (1998).
  • Israel E, Banerjee R, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of Inhaled Glucocorticoids on Bone Density in Premenopausal Women. N EngL J Med. 345,941–947 (2001).
  • Ericson A, Kallen B. Use of drugs during pregnancy — unique Swedish registration method that can be improved. In: Information From the Swedish Medical Products Agency1-7 (2003).
  • Ihre E, Zetterstrom O, Ihre E, Hammarberg B. Voice problems as side effects of inhaled corticosteroids in asthma patients-a prevalence study. J. Voice. 18, 403–414 (2004).
  • Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am. J. &spit: Crit. Care Mea'. 169,855-859 (2004).
  • Pauwels RA, Lofdahl CG, Laitinen LA et aL Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N EngL J. Med. 340, 1948–1953 (1999).
  • •• Large, multicenter randomized clinical trial which studied the effect of the long-term use of budesonide in patients with mild COPD.
  • Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch. Intern. Med. 159,941–955 (1999).
  • Chapman KR, D'Urzo AD, Oedekoven C et aL Effects of deposition of ciclesonide versus placebo on lung function after 12 weeks of treatment in patients with asthma. Am.j Respir. Crit. Care Med. 165, A767—A841 (2002).
  • Chapman KR, Patel P, Boulet LP et al. Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52 week long study. Eur. Respir. 20\(Suppl. 38), 373–340 (2002).
  • Kavuru M, Melamed J, Gross G et aL Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. j Allergy Clin. Immunol. 105,1108–1116 (2000).
  • Lazarus SC, Boushey HA, Fahy JV et aL, Asthma Clinical Research Network for the National Heart, Lung, and Blood Institute. Long-acting 12 agonist monotherapy vs. continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285,2583–2593 (2001).
  • O'Byrne PM, Barnes PJ, Rodriguez-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am. J Respir. Crit. Care Med. 164,1392-1397 (2001).
  • Busse W, Wolfe J, Storms W et al. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. I Fain. Pract. 50,595–602 (2001).
  • Foresi A, Morelli MC, Catena E, for the Italian Study Group. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 117,440–446 (2000).
  • Postma DS, Sevette C, Martinat Y, Schlosser N, Aumann J, Kafe H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur. Respir. J. 17,1083–1088 (2001).
  • Taylor DA, Jensen MW, Kanabar V et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5ct-monophosphate in asthmatic patients. Am. Respir. Crit. Care Med. 160,237-243 (1999).
  • Kanniess F, Richter K, Bohme S et al. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm. PharmacoL Ther 14, 141–147 (2001).
  • Lee DK, Haggart K, Currie GP, Bates CE, Lipworth BJ. Effects of hydrofluoroalkane formulations of ciclesonide 400 pg once daily vs. fluticasone 250 pg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br. J Clin. Pharmacol. 58,26-33 (2004).
  • The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N EngL J. Med. 343, 1054–1063 (2000).
  • •Compared the long-term use of budesonide and nedocromil in children with mild-to-moderate asthma.
  • Pauwels RA, Pedersen S, Busse WW et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 361(9363), 1071–1076 (2003).
  • Chapman KR. The impact of budesonide and other inhaled corticosteroid therapies in the management of asthma in children and adults. Clin. Ther. 25, C2—C14 (2003).
  • Vestbo J, Sorensen T, Lange P, Brix A, Tone P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353, 1819–1823 (1999).
  • Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. 320,1297–1303 (2000).
  • Higgins G. New US asthma guidelines stress early, aggressive treatment. Inpharma 1077,9–10 (1997).
  • Keeley D, Rees J. New guidelines on asthma management. Br. Med. J 314, 315–316 (1997).
  • Busse WW Srebro SH, Edwards L, Johnson MC, Rickard K. Low-dose inhaled fluticasone propionate versus oral zafirlukast in asthma patients. Am. J Respir. Crit. Care Med. 159, A628 (1999).
  • Storms WW Srebro SH, Edwards L, Rickard K. Better asthma symptom control with low-dose inhaled fluticasone propionate than with oral zafirlukast. Am. J Respir. Crit. Care Med. 159,628 (1999).
  • Bleecker ER, Welch MJ, Weinstein SF et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J. Allergy Clin. Immunol. 105,1123–1129 (2000).
  • Malmstrom K, Rodriguez-Gomez G, Guerra J et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann. Intern. Med. 130,487–495 (1999).
  • Stempel DA, Mauskopf T, McLaughlin C, Yazdani C, Stnford RH. Comparison of asthma costs in pateints starting fluticasone propionate compared to patients starting montelukast. Respir. Med. 95,227–234 (2001).
  • Stempel DA, Meyer RV, Stanford R, Yancey S. One year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J. Allergy Clin. immunol. 107, 94–98 (2001).
  • Balkrishnan R, Camacho FL, Schechter MS, Pleasants RA, Bowton D. Costs and benefits associated with initiation of fluticasone versus montelukast as controller therapy in a medicaid asthmatic population. Value Health 5,189 (2002).
  • Holzer SS. Engelhart L, Crown WH, L:Herrou TA, Kennedy ST. Asthma treatment costs using inhaled corticosteroids. Am. J. Manag. Care 3, 891–897 (1997).
  • Barnes NC, Thwaites RMA, Price MJ. The cost effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Respir. Med. 93,402–407 (1999).
  • Stempel DA, Stanford RH, Thwaites R, Price MJ. Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma. Clin. Ther 22,1562–1574 (2000).
  • Lundback B, Jenkins C, Price MJ, Thwaites RM. Cost effectiveness of salmeterol/fluticasone propionate combination product 50/250 pg twice daily and budesonide 800 pg twice daily in the treatment of adults and adolescents with asthma. International Study Group. Respir. Med. 94,724-732 (2000).
  • ••Confirmed the cost effectiveness ofsalbutemol/fluticasone proprionate combination therapy over budesonide therapy in patients with moderate-to-severe asthma.
  • Venables TL, McConchie S, Follows RM. A comparison of the cost effectiveness of budesonide and fluticasone dry powder devices in the management of adult asthma. Br. J. Med. Econ. 11,113–119(1997).
  • Ericsson A, Leuenberger P, Perruchoud AP et al. Budesonide turbuhaler gave lower health costs than fluticasone propionate. Eur. Respir J. 14 (Suppl.), S508 (1999).
  • Smith MJ, Rascati KL, Johnsrud MT. Costs and utilization patterns associated with persistent asthma: a comparison of Texas Medicaid patients with and without continous inhaled corticosteroid treatment. JMCP7, 452–459 (2001).
  • Balkrishnan R, Norwood JG, Anderson A. Outcomes and cost benefit associated with the introduction of inhaled corticosteroid therapy in a Medicaid population of asthmatics. Clin. Ther 20,567–580 (1998).
  • •Showed a definite cost benefit with the introduction of inhaled corticosteroid therapy.
  • Balkrishnan R, Christensen DB. Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease. Clin. Ther 22, 452–469 (2000).
  • ••Emphasizes the importance of medicationadherence as an important factor to bear in mind while performing cost-based studies in an asthmatic population.
  • Balkrishnan R, Christensen DB. Inhaled corticosteroid nonadherence and immediate avoidable medical events in older adults with chronic pulmonary ailments. J Asthma 37,511–517 (2000).
  • Ayres JG, Price MJ, Efthimiou J. Cost- effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial. Respir. Med. 97,212-220 (2003).
  • Highland KB. Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a long-term benefit? CUIT: Opin. Pulm. Med. 10,113–119 (2004).
  • van den Boom G, Rutten-van Molken MP, Molema J, Tirimanna PR, van Weel C, van Schayck CP. The cost effectiveness of early treatment with fluticasone propionate 250 pg twice a day in subjects with obstructive airway disease. Results of the DIMCA program. Am. J Respir. Crit. Care Med. 164,2057-2066 (2001).
  • Tomas LH, Varkey B. Improving health-related quality of life in chronic obstructive pulmonary disease. CUIT: Opin. Pulm. Med. 10(2), 120–127 (2004).
  • Juniper ER Health-related quality of life in asthma. CUIT: Opin. Pulm. Med. 5, 105–110 (1999).
  • Schmier JK, Chan KS, Leidy NK. The impact of asthma on health-related quality of life. J Asthma 35,585–597 (1998).
  • Warschburger P, Busch S, Bauer CP, Kiosz D, Stachow R, Petermann E Health-related quality of life in children and adolescents with asthma: results from the ESTAR Study. J Asthma 41,463–470 (2004).
  • Miravitlles M, Alvarez-Sala JL, Lamarca R et al. Treatment and quality of life in patients with chronic obstructive pulmonary disease. Qual. Life Res. 11, 329–338 (2002).
  • Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Comparison of the responsiveness of different disease-specific health status measures in patients with asthma. Chest 122,1228–1233 (2002).
  • van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J Respir. Crit. Care Med. 166, 1358–1363 (2002).
  • Thompson WH, Carvalho P, Souza JP, Charan NB. Controlled trial of inhaled fluticasone propionate in moderate-to-severe COPD. Lung 180,191–201 (2002).
  • Wise R, Connett J, Weinmann G, Scanlon P, Skeans M. Effect of inhaled triamcinoloneon the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl. J Med. 343,1902–1909 (2000).
  • Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur. Respir. J 23 698–702 (2004).
  • Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur. Respir. j 21,68–73 (2003).
  • Hampel FC Jr, Sugar M, Parasuraman B, Uryniak T, Liljas B. Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) improves health-related quality of life in adults previously receiving inhaled corticosteroids. Adv The': 21,27–38 (2004).
  • Weiss KB, Liljas B, Schoenwetter W, Schatz M, Luce BR. Effectiveness of budesonide administered via dry-powder inhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler for adults with persistent asthma in managed care settings. Clin. Ther 26,102–114 (2004).
  • Creticos PS. Treatment options for initial maintenance therapy of persistent asthma: a review of inhaled corticosteroids and leukotriene receptor antagonists. Drugs 63, 1–20 (2003).
  • •Compares different inhaled corticosteroids with respect to humanistic and clinical outcomes.
  • Orr LC, Fowler SJ, Lipworth BJ. Relationship between changes in quality of life and measures of lung function and bronchial hyper-responsiveness during high-dose inhaled corticosteroid treatment in uncontrolled asthma. Am. j Respir. Med. 2,433–438 (2003).
  • Chuchalin AG, Svensson K, Stahl E et al. A health-related quality of life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia. Respiration 69,427–433 (2002).
  • Juniper EF, Jenkins C, Price MJ, James MH. Impact of inhaled salmeterolThuticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. Am. I Respir. Med. 1, 435–440 (2002).
  • Lyseng-Williamson KA, Plosker GL. Inhaled salmeterolifluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. PharmacoEconomics 21,951–989 (2003) .
  • •Provides an in-depth review of the inhaled salemterol and fluticasone propionate combination.
  • van Grunsven PM, van Schayck CP, Derenne JP et al. Long-term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 54,7–14 (1999)
  • Donohue JF, Kalberg C, Emmett A, Merchant K, Knobil K. A short-term comparison of fluticasone propionateisalmeterol with ipratropium bromideialbuterol for the treatment of COPD. Treat. Respir. Med. 3,173–181 (2004).
  • Lyseng-Williamson KA, Keating GM. Inhaled salmeterolifluticasone propionate combination in chronic obstructive pulmonary disease. Am. j Respir. Med. 1, 273–282 (2002).
  • Mahler DA, Wire P, Horstman D et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. I Respir. Crit. Care Med. 166,1084–1091 (2002).
  • Linus H, Tomas S, Varkey B. Improving health-related quality of life in chronic obstructive pulmonary disease. CUIT: Opin. Fulm. Med. 10,120-127 (2004).
  • Kemp JP. Expected characteristics of an ideal, all-purpose inhaled corticosteroid for the treatment of asthma. Clin. Ther 25, 15–27 (2003).
  • Vestbo J. TORCH Study Group. The TORCH (towards a revolution in COPD health) survival study protocol. Eur. Respir. a124,206–210 (2004).
  • ••Aims to determine the impact ofsalemterolifluticasone propionate combination and the individual components on the survival of COPD patients.

Websites

  • Facts about asthma www.alaw.orgiasthma/facts_about_asthmai (Accessed November 2004)
  • National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2002 Chart Book on Cardiovascular, Lung, and Blood Diseases www. nhlbi.nih.goviresourcesid ocs/02_chtb k.pdf (Accessed November 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.